Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study-Reference-Cited by-同舟云学术

Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study

Published:2024-03-02 Issue:4 Volume:44 Page:289-291
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Carraro Gianni,Di Vico Valentina,Martinetti Loris,Bettin Elisabetta,Cacciapuoti Martina,Stefanelli Lucia Federica,Gobbi Laura,Nalesso Federico,Martino Francesca Katiana,Calò Lorenzo A.^ORCID

Funder

University of Padova

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40261-024-01350-6.pdf

Reference11 articles.

1. Perumareddi P, Trelka DP. autosomal dominant polycystic kidney disease. Prim Care. 2020;47:673–89.

2. Corradi V, Giuliani A, Gastaldon F, de Cal M, Mancini B, Montaldi A, et al. Genetics and autosomal dominant polycystic kidney disease progression. Contrib Nephrol. 2017;190:117–23.

3. Nobakht N, Hanna RM, Al-Baghdadi M, Ameen KM, Arman F, Nobahkt E, et al. Advances in autosomal dominant polycystic kidney disease: a clinical review. Kidney Med. 2020;2:196–208.

4. Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recom-mendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;3:337–48.

5. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018;33:477–89.